{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:13:41Z","timestamp":1769231621770,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.clml.2013.09.010","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:39:04Z","timestamp":1380587944000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"14","author":[{"given":"Mohamed","family":"Shanavas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans A.","family":"Messner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Kamel-Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis (Dong Hwan)","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieun","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lambie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.09.010_bib1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year\u00a0survivors of myeloablative allogeneic hematopoietic cell transplantation for\u00a0chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.010_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705063","article-title":"Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Espa\u00f1ol de Trasplante Hemopoy\u00e9tico)","volume":"36","author":"Mart\u00ednez","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.010_bib4","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V72.6.1978.1978","article-title":"HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration","volume":"72","author":"Martin","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for\u00a0chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2013.09.010_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2006.1.226","article-title":"Managing the patient with chronic myeloid leukemia through and\u00a0after allogeneic stem cell transplantation","author":"Apperley","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2013.09.010_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/bmt.2010.138","article-title":"Role of allo-SCT for CML in 2010","volume":"45","author":"Venepalli","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.010_bib8","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","article-title":"Induction of graft-versus-host disease as\u00a0immunotherapy for relapsed chronic myeloid leukemia","volume":"330","author":"Porter","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.010_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1701224","article-title":"Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors","volume":"21","author":"van Rhee","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.010_bib12","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V99.10.3861","article-title":"Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Olavarria","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib13","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1634\/theoncologist.2009-0297","article-title":"Why doesn't imatinib cure chronic myeloid leukemia?","volume":"15","author":"Redner","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2013.09.010_bib15","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"32","article-title":"Chronic myelogenous leukaemia, BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.clml.2013.09.010_bib16","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.010_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0Proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2013.09.010_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.bmt.1705755","article-title":"Long-term follow-up of allogeneic bone\u00a0marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning","volume":"40","author":"Zaretsky","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.010_bib19","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2002.06.077","article-title":"Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation","volume":"20","author":"Kiss","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.010_bib20","first-page":"663","article-title":"A\u00a0comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation","volume":"91","author":"Weisser","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.09.010_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","article-title":"Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Wright","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.010_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bmt.2012.234","article-title":"Donor lymphocyte infusions for\u00a0the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation","volume":"48","author":"Basak","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.010_bib23","first-page":"3328","article-title":"Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the\u00a0European Group for Blood and Marrow Transplantation","volume":"95","author":"Guglielmi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.010_bib25","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood.V83.11.3377.3377","article-title":"Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse","volume":"83","author":"van Rhee","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib26","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the\u00a0Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2013.09.010_bib28","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.010_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2013.09.010_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3324\/haematol.13353","article-title":"Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation [letter]","volume":"94","author":"Hayat","year":"2009","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501300431X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501300431X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:49Z","timestamp":1761870289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501300431X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S215226501300431X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.09.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}